Enveric Biosciences, Inc. (ENVB) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2000–2008
Loading P/E history...
P/E Ratio Analysis
As of October 17, 2026, Enveric Biosciences, Inc. (ENVB) trades at a price-to-earnings ratio of -0.0x, with a stock price of $1.38 and trailing twelve-month earnings per share of $-2.19.
The current P/E is 100% below its 5-year average of 87.4x. Over the past five years, ENVB's P/E has ranged from a low of 7.5x to a high of 591.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.3x, ENVB trades at a 100% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 152.0x.
Relative to the broader market, ENVB trades at a notable discount to the S&P 500 median P/E of 26.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ENVB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ENVB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ENVB P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $14B | 4648.0 | - | -95% | |
| $2B | 6.3Lowest | 0.61Best | +817%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ENVB Historical P/E Data (2000–2008)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2008 Q2 | Jun 30 2008 | $999999.00 | $53199.48 | 18.8x | -78% |
| FY2008 Q1 | Mar 31 2008 | $999999.00 | $83816.28 | 11.9x | -86% |
| FY2007 Q4 | Dec 31 2007 | $999999.00 | $132810.48 | 7.5x | -91% |
| FY2007 Q3 | Sep 30 2007 | $999999.00 | $128636.52 | 7.8x | -91% |
| FY2007 Q2 | Jun 30 2007 | $999999.00 | $37508.04 | 26.7x | -69% |
| FY2005 Q3 | Sep 30 2005 | $999999.00 | $61852.44 | 16.2x | -81% |
| FY2005 Q2 | - | $999999.00 | $35334.48 | 28.3x | -68% |
| FY2002 Q4 | - | $999999.00 | $4214.04 | 237.3x | +172% |
| FY2002 Q3 | Sep 30 2002 | $999999.00 | $14086.20 | 71.0x | -19% |
| FY2001 Q2 | Jun 30 2001 | $999999.00 | $1691.28 | 591.3x | +577% |
| FY2001 Q1 | Mar 31 2001 | $999999.00 | $49625.04 | 20.2x | -77% |
| FY2000 Q4 | Dec 31 2000 | $999999.00 | $87725.16 | 11.4x | -87% |
Average P/E for displayed period: 87.4x
ENVB Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
26+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ENVB — Frequently Asked Questions
Quick answers to the most common questions about buying ENVB stock.
What is ENVB's P/E ratio?
Enveric Biosciences, Inc. (ENVB) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-2.19. The 5-year average P/E is 87.4x and the historical range spans 7.5x to 591.3x.
Is ENVB stock overvalued or undervalued?
ENVB current P/E: -0.0x. 5-year average P/E: 87.4x. Percentile: 0th.
Is ENVB stock expensive?
ENVB is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 87.4x (0th percentile of historical range).
What is ENVB's historical P/E range?
Over the past 5 years, ENVB's P/E ratio has ranged from 7.5x to 591.3x, with a median of 20.2x and an average of 87.4x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2000–2008.
How does ENVB's P/E compare to the S&P 500?
ENVB current P/E: -0.0x. S&P 500 median P/E: 26.1x.
How does ENVB's valuation compare to Healthcare peers?
Enveric Biosciences, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is ENVB's PEG ratio?
ENVB PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 84.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ENVB's earnings yield?
ENVB earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.